In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche and DeCode Turn To Diagnostics

Executive Summary

Roche Diagnostics has signed a new five-year-alliance with deCode Genetics, in a move that suggests the preliminary success of an earlier agreement between the companies. While the earlier deal, signed in 1998, revolves around finding pharmaceutical targets, the new agreement aims to identify and validate diagnostics targets based on genes associated with common diseases.

You may also be interested in...



Why Does Biotech Ignore the Diagnostics Opportunity?

For the last two decades, diagnostics has been the poor stepsister of pharmaceuticals. But in the era of proteomics, diagnostics will come of age for those companies smart enough to exploit its two major market opportunities: diagnosing diseases which, caught early, can be successfully treated; and selling tests which can identify whether or not a specific drug will work for a particular patient. As their strategic options narrow--platform strategies are now virtually unfinanceable--those biotechs wearing pharmaceutical blinders are ignoring important paths to sustainability.

Roche Diagnostics' New Marker Mandate

Roche Diagnostics is the best performing asset at Roche. As the troubled Swiss pharma company suffers through its worst pipeline drought in a decade, Roche Diagnostics is delivering a stellar performance. It is strong across all business segments, from laboratory systems to diabetes to molecular testing. Its challenge: to pull far enough ahead in its traditional businesses to maintain a comfortable lead. Its bigger hurdle, however, is to position itself as a leader in adoption of new genomic and proteomic diagnostic technologies, which is where the industry's future growth lies.

Roche Seeks Middle Ground in Iceland

What many companies wish for these days is access to a gene pool from a population of patients afflicted with particular diseases--and not the ultra-rare familial diseases academic researchers have been tracking for years. Roche and deCode Genetics find a gene pool they like in Iceland.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV001641

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel